Zynlonta

Active Ingredient(s): Loncastuximab Tesirine-lpyl
FDA Approved: * April 23, 2021
Pharm Company: * ADC Therapeutics SA
Category: Cancer

Loncastuximab tesirine , sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma.[1] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.[1] Loncastuximab tesirine was approved for medical use in the United States in April 2021.[1][2] Contents 1 Medical uses 2 Technology 3 Clinical trials 4 Orphan drug designation 5 Ref... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.